Arvinas Gelecekteki Büyüme
Future kriter kontrolleri 0/6
Arvinas kazanç ve gelirin sırasıyla yıllık 0.3% ve 6.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 8.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -102.7% olacağı tahmin edilmektedir.
Anahtar bilgiler
0.3%
Kazanç büyüme oranı
8.33%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 14.4% |
| Gelir büyüme oranı | 6.5% |
| Gelecekteki özkaynak getirisi | -102.74% |
| Analist kapsamı | Good |
| Son güncelleme | 14 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Analiz Makalesi • May 16
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN)
Arvinas, Inc. ( NASDAQ:ARVN ) shareholders will have a reason to smile today, with the analysts making substantial...Seeking Alpha • May 12
Arvinas: FDA Approval Validates The Platform, But Does Not Signal Near-Term Profitability
Summary Arvinas receives FDA approval for Veppanu, the first PROTAC drug, targeting ER+/HER2- breast cancer with ESR1 mutations. Veppanu’s commercial upside is limited by niche indication, direct competition from Orserdu, and royalty economics split with Pfizer. ARVN’s near-term profitability is unlikely; Veppanu royalties and milestones cannot offset a $230M annual cash burn. A Hold rating is justified by a strong cash runway and de-risked platform, but late-stage pipeline catalysts remain years away. Read the full article on Seeking AlphaAnaliz Makalesi • May 12
Will Arvinas (NASDAQ:ARVN) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Anlatı Güncellemesi • May 01
ARVN: Early Neurology Readouts And Cash Runway Will Drive Bullish Repricing
Analysts have nudged Arvinas' implied price target higher by a few dollars per share, reflecting updated models after recent Q4 results, early approval for Vepdeg, and a fuller view of the upcoming data cycle for programs like ARV-102 and other 2026 readouts. Analyst Commentary Recent Street research on Arvinas clusters around early approval for Vepdeg, the updated Q4 models, and a more detailed path for ARV-102 and other 2026 data events.
Anlatı Güncellemesi • Apr 17
ARVN: Upcoming Neurology Data Readouts Will Challenge Current Share Price Assumptions
Narrative Update on Arvinas Analysts have lifted their average price targets on Arvinas by several dollars per share, into a mid-teens to around $20 range. This reflects updated models after recent quarterly results, a busy calendar of expected ARV-102 data readouts across neurological indications, and views on the company’s multiyear cash runway.Anlatı Güncellemesi • Apr 03
ARVN: 2026 Neurology Readouts And Cash Runway Will Drive Bullish Reassessment
Analysts have modestly raised the Arvinas fair value estimate from $14.56 to $14.88, reflecting higher Street price targets after recent Q4 model updates, expanded program timelines, and detailed cash runway assessments across multiple firms. Analyst Commentary Recent Street research presents a mixed but generally constructive picture for Arvinas, with several firms adjusting price targets higher following the Q4 update and program milestones.
Anlatı Güncellemesi • Mar 20
ARVN: 2026 Neurology Readouts And Cash Runway Will Drive Future Upside
The analyst price target for Arvinas has moved from $18 to $21, with analysts pointing to updated models that reflect revised assumptions around revenue growth, profit margins, and future P/E as they factor in recent quarterly results and upcoming clinical data readouts. Analyst Commentary Recent research updates show a cluster of higher price targets on Arvinas, with bullish analysts pointing to refreshed models following quarterly results and upcoming clinical data.Anlatı Güncellemesi • Mar 05
ARVN: 2026 Neurology Readouts And Cash Runway Will Balance Execution Risks
Narrative Update on Arvinas The analyst price target for Arvinas has moved higher by $1.75, with analysts tying their updated views to refreshed post earnings models, a higher fair value estimate of $14.56, and anticipated 2026 data readouts for ARV-102 and other pipeline programs. Analyst Commentary Recent research updates show a cluster of higher price targets on Arvinas, with analysts revising their models after the latest quarterly report and company updates.Anlatı Güncellemesi • Feb 19
ARVN: New Leadership And Lymphoma Program Will Drive Future Upside
Analysts have maintained their $18.00 price target for Arvinas, with updated assumptions that reflect adjusted views on revenue growth, profit margins, and future P/E expectations. What's in the News Arvinas appointed Randy Teel, Ph.D., as Chief Executive Officer, effective February 12, 2026.Anlatı Güncellemesi • Feb 05
ARVN: Hematology Data And Preclinical Combination Results Will Balance Cash Burn Risks
Analysts have nudged their price target on Arvinas slightly higher to about $12.81 from $12.75, citing updated assumptions around discount rates, revenue contraction, profit margins, and future P/E expectations. What's in the News Arvinas shared preclinical data for ARV-393, an investigational PROTAC BCL6 degrader, in combination with glofitamab at the 67th American Society of Hematology Annual Meeting and Exposition in Orlando, Florida (Key Developments).Analiz Makalesi • Jan 27
Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Anlatı Güncellemesi • Jan 22
ARVN: New Hematology And KRAS Data Will Balance Cash Burn Risks
Narrative Update on Arvinas The analyst price target for Arvinas has moved slightly higher from US$12.44 to US$12.75. Analysts attribute this adjustment to updated assumptions for fair value, discount rate, profit margin, and future P/E.Anlatı Güncellemesi • Jan 07
ARVN: Future Returns Will Balance Breast Cancer Setbacks And Cash Burn Risks
Analysts have nudged their price target for Arvinas slightly higher to about $12.44 from $12.31, while highlighting rising concerns that competitive progress in hormone receptor positive, HER2 negative metastatic breast cancer could leave vepdegestrant at risk of becoming less relevant and keep investor focus on cash burn. Analyst Commentary Bullish Takeaways Bullish analysts point to the updated average price target of about $12.44 as an indication that some on the Street still see room for upside relative to the most cautious views, even as competitive pressure builds around vepdegestrant.Anlatı Güncellemesi • Dec 16
ARVN: Early Neuroscience Pipeline Will Drive Future Upside Despite Breast Cancer Reset
Analysts have sharply cut their price target on Arvinas to about $18 from over $60. The change reflects heightened competitive pressure on vepdegestrant, uncertainty around out-licensing timelines, and a reset of expectations toward the company’s earlier-stage oncology and neuroscience pipeline.Anlatı Güncellemesi • Dec 02
ARVN: Refocus On Neuroscience And Cost Discipline Will Balance Risks And Opportunities
Analysts have revised Arvinas' price target lower. Notable cuts include Goldman's reduction to $6 from $8, reflecting heightened uncertainty around vepdegestrant's outlook and increased competitive pressures in breast cancer therapies.Anlatı Güncellemesi • Nov 18
ARVN: Core Oncology And Neuroscience Focus Will Drive Share Recovery Ahead
Arvinas' analyst price target has been revised downward from approximately $17.44 to $12.31 per share. Analysts cite increased competitive risks for vepdegestrant along with heightened uncertainty surrounding the company's future commercial prospects.Anlatı Güncellemesi • Sep 25
Precision Therapies Will Meet Demand Despite Clinical And Regulatory Risks
Arvinas’ consensus price target was reduced to $17.44, reflecting increased commercialization uncertainty for vepdegestrant following the decision to seek a third-party partner, restructuring, and delays to peak sales estimates despite ongoing support for the early-stage pipeline. Analyst Commentary Recent decision by Arvinas and Pfizer to seek a third-party partner for vepdegestrant has introduced significant uncertainty around commercialization timing and strategy, prompting downside risk to valuation.Analiz Makalesi • Sep 09
Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified
Arvinas, Inc. ( NASDAQ:ARVN ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Analiz Makalesi • Jun 01
We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analiz Makalesi • May 01
Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry
Arvinas, Inc. ( NASDAQ:ARVN ) shareholders are no doubt pleased to see that the share price has bounced 37% in the last...
Yeni Anlatı • Mar 24
Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles
Successful trials and partnerships in oncology could support Arvinas' transition to commercial operations, driving growth and revenue potential.Seeking Alpha • Mar 14
Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects
Summary Arvinas' Vepdegestrant failed to show significant improvement over fulvestrant in the VERITAC-2 trial in the ITT population, leading to a 52% stock drop. Arvinas' enterprise value plummeted to -$400M, with a high cash burn rate and no advanced pipeline candidates to offset losses. Despite a healthy cash balance, the ARVN's burn rate and lack of near-term catalysts make it an unattractive investment; reiterate sell rating. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 12
Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%
Arvinas, Inc. ( NASDAQ:ARVN ) shareholders that were waiting for something to happen have been dealt a blow with a 56...Seeking Alpha • Dec 25
Arvinas' Vepdegestrant: Why The Data May Not Hold Up
Summary Arvinas, Inc. is a clinical-stage biotech firm focusing on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. We believe Arvinas is a short due to weak clinical data for ARV-471, which may not demonstrate compelling efficacy, risking a valuation collapse. Vepdegestrant (ARV-471) shows limited efficacy, likely due to poor bioavailability, and may not outperform existing treatments like fulvestrant in upcoming trials. Given Arvinas' significant cash burn and reliance on ARV-471, we expect a 30-40% stock price decline if Phase 3 results disappoint. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 24
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analiz Makalesi • Nov 28
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)
Arvinas, Inc.'s ( NASDAQ:ARVN ) price-to-sales (or "P/S") ratio of 11.1x might make it look like a strong sell right...Seeking Alpha • Oct 16
Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause
Summary Arvinas, Inc.'s lead candidate, ARV-471, shows promise in phase 3 trials, especially in ESR1 mutant patients, but has mixed results in wild-type ESR1 patients. Despite past poor performance, recent positive data and a strong cash balance make ARVN a cautiously optimistic investment ahead of upcoming phase 3 data. Financially, Arvinas has a market cap of $1.78bn and a cash balance of $1.23bn, providing a runway of 8–9 quarters. While ARVN has potential, past inconsistent data warrants a cautious approach before investing further, despite promising recent developments. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 02
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
A week ago, Arvinas, Inc. ( NASDAQ:ARVN ) came out with a strong set of second-quarter numbers that could potentially...Seeking Alpha • Jul 12
Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive
Summary Arvinas utilizes PROTAC technology to develop protein degraders, with vepdegestrant as a lead drug candidate in Phase 3 studies. Vepdegestrat will read out data from a large, late-stage study in breast cancer patients this year - a major catalyst to look out for. Data shared to date has been somewhat unconvincing and from small subsets - to secure approval, the drug will need to meet an endpoint of progression-free survival. The drug is also being tested in a Phase 3 study alongside Pfizer's Ibrance - some early promising data is not a cast iron guarantee of success. I'm a little lukewarm on Vepdegestrat's prospects and am downgrading my former "buy" rating to hold. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 27
Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Mar 03
Arvinas: Behind The Huge Rally
Summary Today, we take a look at Arvinas, Inc., a biotech company that is focused on developing therapies to degrade disease-causing proteins. Arvinas is partnered with drug giant Pfizer around its lead drug candidate and the stock has more than tripled over the past four months. The company also ended fiscal year 2023 with over $1.25 billion in cash and marketable securities, sufficient to fund activities until 2027. An analysis around Arvinas follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • Feb 25
What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You
Despite an already strong run, Arvinas, Inc. ( NASDAQ:ARVN ) shares have been powering on, with a gain of 28% in the...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 76 | -259 | -213 | -209 | 12 |
| 12/31/2027 | 75 | -253 | -204 | -172 | 17 |
| 12/31/2026 | 122 | -184 | -195 | -165 | 17 |
| 3/31/2026 | 89 | -221 | -257 | -254 | N/A |
| 12/31/2025 | 263 | -81 | -276 | -274 | N/A |
| 9/30/2025 | 312 | -58 | -329 | -327 | N/A |
| 6/30/2025 | 373 | -73 | -399 | -396 | N/A |
| 3/31/2025 | 427 | -47 | -253 | -251 | N/A |
| 12/31/2024 | 263 | -199 | -261 | -259 | N/A |
| 9/30/2024 | 161 | -309 | -260 | -258 | N/A |
| 6/30/2024 | 93 | -323 | -217 | -215 | N/A |
| 3/31/2024 | 71 | -355 | -356 | -354 | N/A |
| 12/31/2023 | 79 | -367 | -351 | -348 | N/A |
| 9/30/2023 | 159 | -295 | -340 | -336 | N/A |
| 6/30/2023 | 158 | -298 | -323 | -318 | N/A |
| 3/31/2023 | 137 | -301 | -313 | -308 | N/A |
| 12/31/2022 | 131 | -282 | -280 | -273 | N/A |
| 9/30/2022 | 127 | -253 | -246 | -238 | N/A |
| 6/30/2022 | 103 | -233 | 503 | 510 | N/A |
| 3/31/2022 | 75 | -213 | 536 | 541 | N/A |
| 12/31/2021 | 54 | -191 | 555 | 559 | N/A |
| 9/30/2021 | 23 | -180 | 562 | 566 | N/A |
| 6/30/2021 | 21 | -164 | -142 | -138 | N/A |
| 3/31/2021 | 21 | -139 | -118 | -112 | N/A |
| 12/31/2020 | 26 | -119 | -96 | -90 | N/A |
| 9/30/2020 | 24 | -99 | -83 | -77 | N/A |
| 6/30/2020 | 47 | -86 | -59 | -53 | N/A |
| 3/31/2020 | 45 | -78 | -52 | -45 | N/A |
| 12/31/2019 | 43 | -70 | N/A | -41 | N/A |
| 9/30/2019 | 42 | -65 | N/A | -37 | N/A |
| 6/30/2019 | 15 | -173 | N/A | -50 | N/A |
| 3/31/2019 | 14 | -179 | N/A | -48 | N/A |
| 12/31/2018 | 14 | -240 | N/A | -16 | N/A |
| 9/30/2018 | 13 | -233 | N/A | 24 | N/A |
| 6/30/2018 | 12 | -114 | N/A | 28 | N/A |
| 3/31/2018 | 10 | -98 | N/A | 31 | N/A |
| 12/31/2017 | 8 | -29 | N/A | 5 | N/A |
| 12/31/2016 | 7 | -12 | N/A | -19 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: ARVN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Kazançlar ve Piyasa: ARVN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Yüksek Büyüme Kazançları: ARVN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Gelir ve Pazar: ARVN şirketinin gelirinin (yıllık 6.5% ) US pazarından (yıllık 11.7% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: ARVN şirketinin gelirinin (yıllık 6.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: ARVN 3 yıl içinde kârsız olması bekleniyor.
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/18 09:14 |
| Gün Sonu Hisse Fiyatı | 2026/05/15 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Arvinas, Inc. 28 Bu analistlerden 17, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Tazeen Ahmad | BofA Global Research |